Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Celltrion has received Phase 3 clinical trial plan approval from the Ministry of Food and Drug Safety (MFDS) of South Korea for CT-P51, a biosimilar candidate to Keytruda, targeting patients with metastatic non-squamous non-small cell lung cancer.
📊 Key Disclosure Content & Financial Highlights
- Overview
- Company: Celltrion, Inc. (Stock Code: 068270)
- Disclosure Type: Major Management Matters Related to Investment Decisions
- Subject: Approval of Phase 3 Clinical Trial Plan for CT-P51 (Keytruda Biosimilar) in South Korea
- Regulatory Body: Ministry of Food and Drug Safety (MFDS), South Korea
- Confirmation Date: 2025-04-28 (Application Date: 2025-01-15)
- Clinical Trial Details
- Study Title: A Double-Blind, Randomized, Active-Controlled, Parallel-Group Phase 3 Trial to Compare the Efficacy and Safety of CT-P51 versus Keytruda in Combination with Platinum-Pemetrexed Chemotherapy in Previously Untreated Patients with Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Phase: Global Phase 3
- Target Indication: Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Registration Number: EU CT number 2024-514048-98-00
- Patient Count: 606 subjects
- Treatment Duration: 2 years
- Purpose: To demonstrate biosimilarity between CT-P51 and the reference drug Keytruda in terms of efficacy and safety
- Investment Risks & Future Plans
- Statistically, the probability of a clinical-stage drug candidate receiving final pharmaceutical approval is approximately 10%.
- Commercialization plans may be modified or abandoned if trial results fail to meet expectations during clinical testing or licensing processes.
- Celltrion aims to expand market reach by seeking authorization across all indications held by the original product.
- Content of this disclosure will be utilized in upcoming press releases and IR materials.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Phase 3 Trial Progression and Follow-up Results
This disclosure serves as notification regarding the IND approval received from South Korea’s MFDS for the global Phase 3 trial of CT-P51. Following this approval, tracking whether clinical procedures such as patient administration proceed as planned and reviewing the resulting efficacy and safety data is essential for determining whether the trial is completed successfully. Relevant updates can be verified through subsequent major management disclosures, periodic reports, or official company IR materials.
📢 Disclaimer & Source Notice
Source: This content was structured and generated based on official disclosure data from the Financial Supervisory Service’s DART system.
Investment Risk Warning: This material is provided for informational and language reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest solely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
